CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Bendamustine hydrochloride|
|Strength||25 mg/vial and 100 mg/vial|
|Indication||Non-Hodgkin lymphoma (NHL)|
|Funding Request||For patients with indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (first line and relapse/refractory)|
|Pre Noc Submission||Yes|
|NOC Date||August 24, 2012|
|Manufacturer||Lundbeck Canada Inc.|
|Sponsor||Lundbeck Canada Inc.|
|Submission Date||April 24, 2012|
|Submission Deemed Complete||May 1, 2012|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||May 8, 2012|
|Check-point meeting||June 27, 2012|
|pERC Meeting||September 20, 2012|
|Initial Recommendation Issued||October 4, 2012|
|Feedback Deadline ‡||October 19, 2012|
|pERC Reconsideration Meeting||November 15, 2012|
|Final Recommendation Issued||November 29, 2012|
|Notification to Implement Issued||December 14, 2012|
|Therapeutic Area||Non-Hodgkin Lymphoma and Mantle Cell Lymphoma|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.